Literature DB >> 19524069

Association between specific HIV-1 Env traits and virologic control in vivo.

Beda Joos1, Philip Rieder, Marek Fischer, Herbert Kuster, Peter Rusert, Alexandra Trkola, Satish K Pillai, Joseph K Wong, Rainer Weber, Huldrych F Günthard.   

Abstract

HIV RNA levels are influenced by genetic characteristics of both the host and the virus. Here we applied machine learning techniques to determine if plasma-derived HIV-1 amino acid sequences can be used to predict spontaneous virologic control. We studied the relationship between HIV-1 env genotype and viral load in 20 chronically infected patients undergoing treatment interruptions (SSITT, Swiss-Spanish Intermittent Treatment Trial) and in 104 primary HIV infected (PHI) patients before antiretroviral therapy (cART) and where applicable also after treatment stop. Extensive longitudinal sampling during the interruptions was performed in nine SSITT patients. Sequences obtained from these nine patients during the first virus rebound were used as a training data set and revealed a strong genetic signature (accuracy 98.6% in cross-validation) associated with control of viremia at levels below 5000copies/mL of viral RNA maintained for at least 2 months after the final cART stop. The simple sequence pattern at gp120 positions 268E/358T was confirmed to be predictive of control in the clonal sequences originating from these patients during all subsequent rebounds. Sequences from the remaining 11 SSITT patients with less frequent sampling and from the PHI patients were used for external validation. High sensitivities (71-100%) and negative predictive values (80-100%) but low positive predictive values (12-40%) were achieved in the patient-wise analysis which was based on presence of the genetic pattern in all clones. These results suggest that presence of virus lacking the amino acid pattern 268E/358T is associated with VL >5000 at baseline of PHI and with low probability of spontaneous virologic control after treatment stop. Conversely, however, presence of 268E/358T does not predict control of viremia. These residues in HIV gp120 might affect in vivo HIV-1 fitness either at the level of Env function or influence susceptibility to adaptive or innate immune response. 2009 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19524069      PMCID: PMC3918463          DOI: 10.1016/j.meegid.2009.06.002

Source DB:  PubMed          Journal:  Infect Genet Evol        ISSN: 1567-1348            Impact factor:   3.342


  29 in total

1.  Stimulation of HIV-specific cellular immunity by structured treatment interruption fails to enhance viral control in chronic HIV infection.

Authors:  Annette Oxenius; David A Price; Huldrych F Günthard; Sara J Dawson; Catherine Fagard; Luc Perrin; Marek Fischer; Rainer Weber; Montserrat Plana; Felipe García; Bernard Hirschel; Angela McLean; Rodney E Phillips
Journal:  Proc Natl Acad Sci U S A       Date:  2002-10-07       Impact factor: 11.205

2.  A new perspective on V3 phenotype prediction.

Authors:  Satish Pillai; Benjamin Good; Douglas Richman; Jacques Corbeil
Journal:  AIDS Res Hum Retroviruses       Date:  2003-02       Impact factor: 2.205

3.  HIV rebounds from latently infected cells, rather than from continuing low-level replication.

Authors:  Beda Joos; Marek Fischer; Herbert Kuster; Satish K Pillai; Joseph K Wong; Jürg Böni; Bernard Hirschel; Rainer Weber; Alexandra Trkola; Huldrych F Günthard
Journal:  Proc Natl Acad Sci U S A       Date:  2008-10-20       Impact factor: 11.205

4.  Consistent viral evolutionary changes associated with the progression of human immunodeficiency virus type 1 infection.

Authors:  R Shankarappa; J B Margolick; S J Gange; A G Rodrigo; D Upchurch; H Farzadegan; P Gupta; C R Rinaldo; G H Learn; X He; X L Huang; J I Mullins
Journal:  J Virol       Date:  1999-12       Impact factor: 5.103

5.  Shifts in cell-associated HIV-1 RNA but not in episomal HIV-1 DNA correlate with new cycles of HIV-1 infection in vivo.

Authors:  Marek Fischer; Alexandra Trkola; Beda Joos; Roland Hafner; Helen Joller; Mark A Muesing; David R Kaufman; Esther Berli; Bernard Hirschel; Rainer Weber; Huldrych F Günthard
Journal:  Antivir Ther       Date:  2003-04

6.  A prospective trial of structured treatment interruptions in human immunodeficiency virus infection.

Authors:  Catherine Fagard; Annette Oxenius; Huldrych Günthard; Felipe Garcia; Michelle Le Braz; Gabriel Mestre; Manuel Battegay; Hansjakob Furrer; Pietro Vernazza; Enos Bernasconi; Amalio Telenti; Rainer Weber; Dominique Leduc; Sabine Yerly; David Price; Sara J Dawson; Thomas Klimkait; Thomas V Perneger; Angela McLean; Bonaventura Clotet; Jose M Gatell; Luc Perrin; Montserrat Plana; Rodney Phillips; Bernard Hirschel
Journal:  Arch Intern Med       Date:  2003-05-26

7.  HIV RNA in plasma rebounds within days during structured treatment interruptions.

Authors:  Marek Fischer; Roland Hafner; Christine Schneider; Alexandra Trkola; Beda Joos; Helen Joller; Bernard Hirschel; Rainer Weber; Huldrych F Günthard
Journal:  AIDS       Date:  2003-01-24       Impact factor: 4.177

8.  Emergence of minor populations of human immunodeficiency virus type 1 carrying the M184V and L90M mutations in subjects undergoing structured treatment interruptions.

Authors:  Karin J Metzner; Sebastian Bonhoeffer; Marek Fischer; Rose Karanicolas; Kristina Allers; Beda Joos; Rainer Weber; Bernard Hirschel; Leondios G Kostrikis; Huldrych F Günthard
Journal:  J Infect Dis       Date:  2003-11-03       Impact factor: 5.226

9.  Human immunodeficiency virus type 1 fitness is a determining factor in viral rebound and set point in chronic infection.

Authors:  Alexandra Trkola; Herbert Kuster; Christine Leemann; Claudia Ruprecht; Beda Joos; Amalio Telenti; Bernhard Hirschel; Rainer Weber; Sebastian Bonhoeffer; Huldrych F Günthard
Journal:  J Virol       Date:  2003-12       Impact factor: 5.103

10.  Improved coreceptor usage prediction and genotypic monitoring of R5-to-X4 transition by motif analysis of human immunodeficiency virus type 1 env V3 loop sequences.

Authors:  Mark A Jensen; Fu-Sheng Li; Angélique B van 't Wout; David C Nickle; Daniel Shriner; Hong-Xia He; Sherry McLaughlin; Raj Shankarappa; Joseph B Margolick; James I Mullins
Journal:  J Virol       Date:  2003-12       Impact factor: 5.103

View more
  1 in total

1.  Assessing predicted HIV-1 replicative capacity in a clinical setting.

Authors:  Roger D Kouyos; Viktor von Wyl; Trevor Hinkley; Christos J Petropoulos; Mojgan Haddad; Jeannette M Whitcomb; Jürg Böni; Sabine Yerly; Cristina Cellerai; Thomas Klimkait; Huldrych F Günthard; Sebastian Bonhoeffer
Journal:  PLoS Pathog       Date:  2011-11-03       Impact factor: 6.823

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.